In-vivo Prime Editing Platform Market Report 2026

In-vivo Prime Editing Platform Market Overview

• In-vivo Prime Editing Platform market size has reached to $1.26 billion in 2025 • Expected to grow to $4.52 billion in 2030 at a compound annual growth rate (CAGR) of 29.1% • Growth Driver: Surge In Rise In Demand For Precise And Efficient Genome Editing Solutions Fueling the Growth of the Market due to Expanding Clinical Adoption • Market Trend: Innovations In Delivery Systems Improve Targeting And Accessibility Of In-Vivo Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under In-vivo Prime Editing Platform Market?

The in-vivo prime editing platform is a cutting-edge genome editing technology that enables precise and targeted modifications of DNA directly within living organisms. It combines a catalytically impaired CRISPR-Cas enzyme with a reverse transcriptase and uses a prime editing guide RNA (pegRNA) to introduce specific base changes, insertions, or deletions without creating double-strand breaks. This approach allows for accurate correction of genetic mutations in tissues or organs, offering significant potential for therapeutic applications, particularly in treating inherited genetic disorders. The main product types in the in-vivo prime editing platform include prime editing enzymes, guide ribonucleic acids (gRNAs), delivery systems, and other related products. Prime editing enzymes are engineered proteins created by fusing CRISPR-associated protein 9 nickase (Cas9 H840A) with reverse transcriptase (RT), often derived from Moloney murine leukemia virus reverse transcriptase (M-MLV RT). In this system, the Cas9 nickase introduces a single-strand break in DNA, while the reverse transcriptase uses an RNA template to directly write the intended change. This enables precise search-and-replace genome editing without double-strand breaks, significantly improving both safety and efficiency. Demand for prime editing enzymes is rising as clinical gene editing advances.

What Is The In-vivo Prime Editing Platform Market Growth Forecast?

The in-vivo prime editing platform market size is expected to see exponential growth in the next few years. It will grow to $4.52 billion in 2030 at a compound annual growth rate (CAGR) of 29.1%. The growth in the forecast period can be attributed to clinical translation of prime editing, expansion of in-vivo gene therapies, regulatory support for genetic treatments, partnerships between biotech and pharma, innovation in delivery vectors. Major trends in the forecast period include advancement in precision genome editing, expansion of gene therapy research, growing focus on rare disease treatment, development of improved delivery systems, increased preclinical and clinical studies.

Global In-vivo Prime Editing Platform Market Segmentation

1) By Product Type: Prime Editing Enzymes, Guide Ribonucleic Acids, Delivery Systems, Other Product Types 2) By Application: Genetic Disease Treatment, Oncology, Rare Diseases, Research And Development 3) By Delivery Method: Viral Vectors, Non-Viral Methods, Lipid Nanoparticles, Other Delivery Method Types 4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-Users Subsegments: 1) By Prime Editing Enzymes: Cas9 Nickeas, Reverse Transcriptase, Engineered Variants 2) By Guide Ribonucleic Acids: pegRNA (Prime Editing Guide RNA), sgRNA (Single Guide RNA), Optimized Synthetic RNAs 3) By Delivery Systems: Viral Vectors (AAV, Lentivirus), Non-Viral Vectors (Lipid Nanoparticles, Electroporation, Physical Methods), Exosomes 4) By Other Product Types: Screening Tools, Assay Kits, Supporting Reagents

What Is The Driver Of The In-vivo Prime Editing Platform Market?

The rise in demand for precise and efficient genome editing solutions is expected to propel the growth of the in-vivo prime editing platform market going forward. Precise and efficient genome-editing means making accurate, targeted changes to DNA (deoxyribonucleic acid), the molecule that stores genetic information in cells, while minimizing off-target edits and unintended consequences. The rise in demand for precise and efficient genome-editing solutions is driven by the growing need for targeted therapies that minimize errors and deliver lasting clinical outcomes. In-vivo prime editing platform supports this demand by enabling highly accurate, targeted DNA corrections inside living tissues with reduced off-target effects and the potential for long-term therapeutic benefit. For instance, according to the World Economic Forum, a Switzerland-based international non-profit organization, there were over 2,000 gene therapies in development worldwide, which was double the number from just three years earlier. Therefore, a rise in demand for precise and efficient genome editing solutions drive the growth of the in-vivo prime editing platform industry.

Key Players In The Global In-vivo Prime Editing Platform Market

Major companies operating in the in-vivo prime editing platform market are AstraZeneca PLC, Danaher Corporation, Regeneron Pharmaceuticals Inc., Moderna Inc., Integrated DNA Technologies Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Maravai LifeSciences Holdings Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Precision BioSciences Inc., Metagenomi Inc., Tessera Therapeutics Inc., Mammoth Biosciences Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc. (NTLA), Caribou Biosciences Inc., Scribe Therapeutics Inc., EGENESIS INC., Prime Medicine Inc., Cellectis S.A.

Global In-vivo Prime Editing Platform Market Trends and Insights

Major companies and research institutions operating in the in-vivo prime editing platform market are focusing on innovations in delivery systems, such as lipid nanoparticles, viral vectors, and engineered extracellular vesicles, to gain a competitive advantage. Lipid nanoparticles and other advanced carriers encapsulate prime editing components, including Cas9 nickase, reverse transcriptase, and pegRNAs, protecting them from degradation and enabling efficient delivery into target cells while improving uptake and tissue specificity. For instance, in September 2023, Moderna, a US-based biotechnology company, demonstrated that optimized lipid nanoparticle formulations can deliver prime editing machinery to liver and muscle tissues in animal models with high precision, achieving targeted genome modifications while minimizing off-target effects. Such advances illustrate how delivery innovations strengthen the efficiency, precision, and future therapeutic potential of in-vivo prime editing therapies.

What Are Latest Mergers And Acquisitions In The In-vivo Prime Editing Platform Market?

In July 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired Verve Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Eli Lilly and Company aims to transform the treatment paradigm for cardiovascular disease by developing one-time, durable genetic therapies that deliver lifelong cardiovascular risk reduction. Verve Therapeutics, Inc. is a US-based clinical-stage biotechnology company that develops genetic medicines for cardiovascular disease using gene editing technologies.

Regional Outlook

North America was the largest region in the in-vivo prime editing platform market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the In-vivo Prime Editing Platform Market?

The in-vivo prime editing platform market consists of revenues earned by entities by providing services such as gene sequencing, genetic analysis, CRISPR -based editing, therapeutic development, preclinical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-vivo prime editing platform market also includes sales of gene editing kits, reagents, enzymes, plasmids, delivery vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.